Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 6Breast 5Thoracic 3Gynecologic 3Sarcoma 2Genitourinary 2Dermatologic 2Tumor-Agnostic 1Plasma cell 1Other solid neoplasm 1Other hematologic neoplasm 1Head & Neck 1

Conditions

Prostatic Neoplasms 1Adenocarcinoma of the Prostate 1

Interventions

Docetaxel 229Radiotherapy 206Magnetic Resonance Spectroscopy 204Radiosurgery 176Gemcitabine 155pembrolizumab 151Nivolumab 147enzalutamide 140Prednisone 129Cisplatin 123Leuprolide 119Androgen Antagonists 117Abiraterone Acetate 114Sunitinib 106Specimen Handling 94Surveys and Questionnaires 91Goserelin 91bicalutamide 90Carboplatin 88Ipilimumab 82gallium 68 PSMA-11 80Blood Specimen Collection 78Everolimus 73apalutamide 72Radiation 71Standard of Care 68Biopsy 68acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 66Paclitaxel 64Cyclophosphamide 62

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × STA 9090 × Genitourinary × Clear all
NCT01270880 2018-09-18

Hsp90 Inhibitor STA-9090 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy

Barbara Ann Karmanos Cancer Institute

Phase 2 Completed
18 enrolled 8 charts
Genitourinary

Prostatic Neoplasms

NCT01368003 2015-09-01

STA-9090 in Castration-Resistant Prostate Cancer With Assessment of Androgen Receptor Pathway Signaling

Dana-Farber Cancer Institute

Phase 2 Withdrawn
Genitourinary

Adenocarcinoma of the Prostate

Data powered by HemOnc (CC BY 4.0) Colophon âš¡